On March 1, 2023 Cellectis (Euronext Growth: ALCLS – Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, reported that it will report financial results for the fourth quarter and year-end 2022 ending December 31st, 2022, on Wednesday, March 8, 2023, after the close of the US market (Press release, Cellectis, MAR 1, 2023, View Source [SID1234627997]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The announcement will be followed by a conference call and live audio webcast on Thursday, March 9, 2023, at 8:00 AM ET / 2:00 PM CET. The call will include the Company’s fourth quarter results, year-end results, and an update on business activities. Details for the call are as follows:
Dial-in information:
Domestic: 1-877-451-6152
International: 1-201-389-0879
Webcast: View Source;passcode=13727032&h=true&info=company-email&r=true&B=6